You are here

vaccines

GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners

GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners

Fierce Pharma

drug manufacturing

Flag link:

AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica production deal

AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica production deal

Fierce Pharma

University of Oxford

drug manufacturing

Flag link:

Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity

Novavax Makes a $167 Million Purchase to Boost Its Coronavirus Vaccine Production Capacity

Motley Fool

drug manufacturing

Flag link:

U.S. is ahead of China in vaccine race, former FDA chief says

U.S. is ahead of China in vaccine race, former FDA chief says

Politico

drug development

Flag link:

Poll: 60% Of US Adults Plan To Get Flu Vaccine, Now Pharmacies Are Preparing For A Rush

Poll: 60% Of US Adults Plan To Get Flu Vaccine, Now Pharmacies Are Preparing For A Rush

Forbes

Flag link:

Merck leaps into Covid-19 vaccine race, aiming to test two different candidates this year

Merck leaps into Covid-19 vaccine race, aiming to test two different candidates this year

Stat

Flag link:

He experienced a severe reaction to Moderna’s Covid-19 vaccine candidate. He’s still a believer

He experienced a severe reaction to Moderna’s Covid-19 vaccine candidate. He’s still a believer

Stat

Moderna Therapeutics

clinical trials

Flag link:

Oxford Uni coronavirus vaccine ‘has 50% chance of success’

Oxford Uni coronavirus vaccine ‘has 50% chance of success’

Pharmaforum

University of Oxford

clinical trials

Flag link:

FDA veteran reassigned to vaccine efforts

FDA veteran reassigned to vaccine efforts

Beckers Hospital Review

Flag link:

Novavax Is Beginning Clinical Trials Of Its Coronavirus Vaccine

Novavax Is Beginning Clinical Trials Of Its Coronavirus Vaccine

Forbes

clinical trials

Flag link:

Can Moderna Win the Race to Find a COVID-19 Vaccine?

Can Moderna Win the Race to Find a COVID-19 Vaccine?

Motley Fool

Moderna Therapeutics

Flag link:

AstraZeneca's COVID-19 vaccine enters phase 2/3 clinical trial

AstraZeneca's COVID-19 vaccine enters phase 2/3 clinical trial

Fierce Biotech

University of Oxford

clinical trials

Flag link:

Moderna Shares Up Almost 250% This Year as Vaccine Trials Continue

Moderna Shares Up Almost 250% This Year as Vaccine Trials Continue

Motley Fool

Flag link:

AstraZeneca Receives $1 Billion From U.S. Government To Produce Oxford Coronavirus Vaccine

AstraZeneca Receives $1 Billion From U.S. Government To Produce Oxford Coronavirus Vaccine

Forbes

federal government

University of Oxford

Flag link:

Harvard animal studies suggest COVID-19 protection can come from previous infection or DNA vaccine

Harvard animal studies suggest COVID-19 protection can come from previous infection or DNA vaccine

Fierce Biotech

Flag link:

AstraZeneca signed up to deliver U.K. shots first. Now it aims to supply COVID-19 vaccine worldwide: report

AstraZeneca signed up to deliver U.K. shots first. Now it aims to supply COVID-19 vaccine worldwide: report

Fierce Pharma

University of Oxford

Flag link:

More questions than answers as Moderna's coronavirus vaccine speeds ahead

More questions than answers as Moderna's coronavirus vaccine speeds ahead

BioPharma Dive

Moderna Therapeutics

clinical trials

Flag link:

Moderna Plans to Raise $1.25 Billion in a Secondary Offering

Moderna Plans to Raise $1.25 Billion in a Secondary Offering

Motley Fool

Moderna Therapeutics

Flag link:

AstraZeneca Aims for 30 Million Doses of COVID-19 Vaccine for U.K. by September

AstraZeneca Aims for 30 Million Doses of COVID-19 Vaccine for U.K. by September

BioSpace

University of Oxford

Flag link:

Moderna Reveals ‘Positive’ Data In Coronavirus Vaccine Trial, Markets Spike

Moderna Reveals ‘Positive’ Data In Coronavirus Vaccine Trial, Markets Spike

Forbes

Moderna Therapeutics

clinical trials

Flag link:

Pages